Cargando…
REST, not REST4, is a risk factor associated with radiotherapy plus chemotherapy efficacy in glioma
BACKGROUND/AIM: Repressor element silencing transcription factor (REST) is a transcription repressor, expressed in several malignancies. This study aims to evaluate the prognostic values of REST and its splicing variant REST4 in glioma, and investigate the potential correlation between REST and REST...
Autores principales: | Li, Cuilin, Zou, Hecun, Wang, Zhifei, Tang, Xinyue, Fan, Xitang, Zhang, Ke, Liu, Jianqiu, Li, Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968789/ https://www.ncbi.nlm.nih.gov/pubmed/29861627 http://dx.doi.org/10.2147/DDDT.S161602 |
Ejemplares similares
-
P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas
por: Zou, Hecun, et al.
Publicado: (2018) -
REST Is Not Resting: REST/NRSF in Health and Disease
por: Jin, Lili, et al.
Publicado: (2023) -
Systematic analysis identifies REST as an oncogenic and immunological biomarker in glioma
por: Wang, Guan, et al.
Publicado: (2023) -
Efficacy and safety of consolidation chemotherapy during the resting period in patients with local advanced rectal cancer
por: Liang, Huan-Qing, et al.
Publicado: (2019) -
The survival benefit of intensified full-dose XELOX chemotherapy concomitant to radiotherapy and then resting-period consolidation chemotherapy in locally advanced rectal cancer
por: Zheng, Rong, et al.
Publicado: (2019)